Evidence map›Paper›PMID 33015544›Full record

ArticleBMC rheumatology2020

Serum protein biomarkers for juvenile dermatomyositis: a pilot study.

Shefa M Tawalbeh, Wilfredo Marin, Gabrielle A Morgan, Utkarsh J Dang, Yetrib Hathout, Lauren M Pachman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy.Current treatment options in rheumatology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shefa M Tawalbeh *Biomedical Engineering Department, State University of New York at Binghamton, Binghamton, New York USA.
Wilfredo Marin *Department of Pediatrics, Northwestern's Feinberg School of Medicine, Division of Pediatric Rheumatology, Ann and Robert H. Lurie Children's Hospital; Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children's Research Institute of Chicago, Chicago, IL USA.
Gabrielle A Morgan *Department of Pediatrics, Northwestern's Feinberg School of Medicine, Division of Pediatric Rheumatology, Ann and Robert H. Lurie Children's Hospital; Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children's Research Institute of Chicago, Chicago, IL USA.
Utkarsh J DangSchool of Pharmacy and Pharmaceutical Sciences, State University of New York at Binghamton, Binghamton, Johnson City, New York USA.
Yetrib HathoutSchool of Pharmacy and Pharmaceutical Sciences, State University of New York at Binghamton, Binghamton, Johnson City, New York USA.ORCID 0000-0002-7549-0476
Lauren M PachmanDepartment of Pediatrics, Northwestern's Feinberg School of Medicine, Division of Pediatric Rheumatology, Ann and Robert H. Lurie Children's Hospital; Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children's Research Institute of Chicago, Chicago, IL USA.
Binghamton University · USLurie Children's Hospital · US

Funding

Dissociation of efficacy from side effects of anti-inflammatory therapies in Duchenne muscular dystrophyP50HD090254 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI VAN DEN ANKER, JOHANNES NICOLAAS · 2019 to 2020
$1.6M
Definition of pharmacodynamic biomarkers for juvenile dermatomyositis for clinical trialsR43AR073547 · NIAMS · REVERAGEN BIOPHARMA, INC. · PI HOFFMAN, ERIC P., PACHMAN, LAUREN M. · 2018 to 2018
$225k
NIAMS NIH HHS R43 AR073547NICHD NIH HHS P50 HD090254
6 · The paper itself

Abstract

backgroundBlood accessible biomarkers to assess disease activity and their response to therapies in Juvenile Dermatomyositis (JDM) are urgently needed. This pilot study aims to identify serum protein biomarkers associated with clinical disease activity in untreated JDM and their response to medical therapy.

methodsSomaScan® technology screened JDM patients for 1305 proteins at three points: 1) before start of treatment, 2) while on therapy, and 3) after treatment tapering when patients were clinically inactive. To define disease associated biomarkers, SomaScan® data from untreated JDM patients (

resultsComparison of untreated JDM versus healthy controls identified 202 elevated and 49 decreased serum proteins in JDM patients with an adjusted

conclusionsBlood accessible protein biomarkers reflecting JDM pathophysiology were identified; some of them rebounded after therapy was tapered. Further studies bridging these biomarkers to specific clinical features of JDM are required to confirm the clinical utility of these serum protein biomarkers.

Indexed as

BiomarkersJuvenile dermatomyositisPharmacodynamic biomarkersSerum proteomicsSomaScan®

Identifiers

PMID33015544
PMCPMC7528471
OpenAlexW3091354476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.